Please login to the form below

Not currently logged in
Email:
Password:

sarilumab

This page shows the latest sarilumab news and features for those working in and with pharma, biotech and healthcare.

Regeneron’s Dupixent and Praluent fall short

Regeneron’s Dupixent and Praluent fall short

And another new launch - Kevzara (sarilumab) for rheumatoid arthritis - also missed expectations and made just $12m.

Latest news

More from news
Approximately 8 fully matching, plus 17 partially matching documents found.

Latest Intelligence

  • Going the distance Going the distance

    Further down the line should come other Regeneron collaborations - first the IL-6 inhibitor sarilumab for rheumatoid arthritis and then dupilumab, which targets the IL-4 pathway that's responsible for

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Six Degrees Medical Consulting

Partnering with top global pharmaceutical companies, we push the boundaries to create meaningful, impactful and lasting learning opportunities. We leverage...

Latest intelligence

Digital trends in B2B sales - how far behind is Pharma?
The modern approach to B2B sales is data-driven, and enabled by digital tools....
The rise of vertical integration in the US payer landscape
Is it a solution to addressing the challenges of the value-based marketplace?...
Light_bulb_Stock_Market.jpg
Creativity has lost its worth
Creativity has lost its worth, and sadly it is undermining effectiveness...

Infographics